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Objective: To describe post-CyberKnifeW imaging characteristics of liver metastases as an aid in assessing response
to treatment, and a novel set of combined criteria (CC) as an alternative to response according to change in size
(RECIST).
Subjects and Methods: Imaging data and medical records of 28 patients with 40 liver metastases treated with
stereotactic body radiotherapy (SBRT) were reviewed. Tumor size, CT attenuation coefficient, and contrast
enhancement of lesions were evaluated up to 2 years post SBRT. Rates of local control, progression-free survival,
time to progression, and overall survival according to RECIST and CC were estimated.
Results: Complete response (CR) was 3.6% (95% CI: 0.1–18%) and 18% (95% CI: 6–37%) according to RECIST and
combined criteria, respectively. Two progressive diseases and two partial responses according to RECIST were
classified as CR by the combined criteria and one stable response according to RECIST was classified as progressive
by CC (Stuart-Maxwell test, p = 0.012). The disease control rate was 60.7% (95% CI: 41–78%) by RECIST and 64%
(95% CI: 44%–81%) by CC.
Conclusion: Use of response criteria based on change in size alone in the interpretation of liver response to SBRT
may be inadequate. We propose a simple algorithm with a combination of criteria to better assess tumor response.
Further studies are needed to confirm their validity.
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Stereotactic body radiotherapy (SBRT) is a technique
that allows the delivery of a precise dose to a tumor
while sparing adjacent normal tissues. Its use for
cerebral metastases has shown high local control rates
of more than 80–90% [1]. The use of stereotaxy in the
treatment of intra-abdominal organs, however, has been
hampered by the movement of these organs along with
respiration. Robotic SBRT with the CyberKnifeW System
(Accuray Incorporated, Sunnyvale, CA) is a technique
that allows tracking of the respiratory motion, thus* Correspondence: h-jarraya@o-lambret.fr
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reproduction in any medium, provided the orenabling delivery of the dose with accuracy even while
the patient breathes freely [2].
The standard first-line treatment for liver metastases is
surgery. Yet less than 20% of liver metastases are surgically
removable because of their often too large size. The diffi-
culty of the surgical access can be due to anatomic
localization of the tumor or other associated comorbidities
present with the patient [3]. Other available therapeutic
options for inoperable liver metastases are intra-arterial
chemo-embolization, Y90 radio-embolization, radiofre-
quency ablation, and ethanol injection [3,4]. Stereotactic
body radiotherapy (SBRT) is an additional alternative mo-
dality that has emerged thanks to recent advances in med-
ical technology and robotics, and appears to result in
favorable liver tolerance and good response rates [5-9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the treatment with imaging is of utmost importance,
because under- or over-interpretation of the response
may have severe consequences, such as subjecting the
patient to unnecessary chemotherapy, or an unnoticed
recurrence. Hepatic tumors display certain unusual
characteristics upon treatment with SBRT, therefore,
interpretation of response using the usual size-based
guidelines has been difficult in the case of liver
treatments.
In this article, we describe post-therapeutic trans-
formations of secondary hepatic lesions treated with
CyberKnife with the objective of identifying new criteria




Between July 2007 and November 2010, 103 patients
with liver metastases, ineligible for surgery or radio-
frequency ablation, underwent SBRT at our center.
Inclusion criteria were: WHO performance status score
less than 3, four hepatic lesions or less, and initial lesion
size smaller than 100 mm. The delivered dose was
40 Gy in four fractions at the beginning, and then
increased to 45 Gy in three fractions.
Among these patients, 28 patients were eligible for
this study: initial and at least two successive follow-up
contrast-enhanced CT (CECT) examinations after treat-
ment, no concomitant chemotherapy, a minimum initial
target lesion size of 10 mm, as for RECIST criteria.
The medical records and image data were reviewed
retrospectively by our internal review board including
one radiologist and two radiation oncologists.
Portal phase images for 28 patients who presented
with 40 initial lesions and 163 follow-up evaluations on
CECT scans (performed every 3 months after treat-
ment) were reviewed. CT scans were obtained with a
16-detector row CT scanner (Sensation 16; Siemens
Medical Solutions). Detector collimation was 1.5 mm.
Tube potential was 120 kV, tube current-time product
was 185 mAs, pitch was 0.75, section thickness was 5 mm,
and reconstruction increment was 5 mm.
Image analysis
Lesion size
Lesion sizes were measured at the longest cross-
sectional dimension of each lesion at each time point.
Response for each lesion (LR) was evaluated at each of
the 163 follow-up evaluations for each of the 40 lesions
as the percent change from the pretreatment evalu-
ation and classified according to the same cut-off
points as used for RECIST [10]. The RECIST criteria
was also calculated for each patient ignoring othermetastatic sites: complete response (CR), disappear-
ance of all hepatic lesions; partial response (PR), more
than a 30% decrease in the sum of the longest diameter
of hepatic lesions from baseline; stable disease (SD),
neither partial response nor progressive disease; and
progressive disease (PD), more than a 20% increase in
the sum of the longest diameter of hepatic lesions from
nadir [10].CT Attenuation coefficients
CT attenuation coefficient (density) of each lesion was
measured in Hounsfield units (H) by drawing a region of
interest circumscribing the margin of each lesion (the
hypodense area). In patients scanned using the triphasic
technique, the portal venous phase images were used for
the lesion density measurements. Before measuring the
lesions’ CT attenuation coefficients, the reproducibility
of different monitors (CT operator’s console [Siemens]
and workstation in a radiologist’s office) were tested
using acrylic, water, and air phantoms. No significant
differences were found in the CT attenuation coefficients
of the phantoms measured on different monitors.
Necrosis was defined as non-enhancing tissue. A max-
imum increase of 10 H on CT after contrast administra-
tion (comparing non-enhancing and enhancing CT
scans at the same level of the lesion) was considered
necrotic tissue, since this was considered insignificant
[11]. Contrast enhancement was categorized based on
its shape as explained in the results section under
imaging findings.Treatment response
Two methods were used to assess treatment response of
each lesion: the size-based criteria, which was based
solely on change in size, and a combination criteria
based on the enhancement pattern of the lesion as well
as its size. At each follow-up evalaution, a first analysis
concerning each individual lesion and a second analysis
concerning the status of all lesions for each of the 28
patients (RECIST) were performed. The combination
criteria (Table 1) consisted of the following: complete
response, disappearance of all lesions or total necrosis
(independent of size) (cCR); partial response, more than
a 30% decrease in lesion size and no total necrosis and
no lobulated enhancement (cPR); stable disease, neither
cPR nor cPD (cSD); and progressive disease, more than
a 20% increase in lesion size and no total necrosis, or
the presence of lobulated enhancement (cPD). For
patients with multiple lesions, RECIST criteria was used
for all lesions and patients were classified as progressive
if a lobulated enhancement was seen for at least one
lesion. These patients were classified in complete
response only if all of the lesions were necrotic.
Table 1 Treatment response according to lesion size, contrast enhancement, necrosis, and combined criteria
Treatment
response
Lesion size Contrast Enhancement Necrosis Combined criteria
Complete response Disappearance of lesion - Total
necrosis
Disappearance of lesion OR Total necrosis
Partial response ≥ 30% decrease - - ≥ 30% decrease
Stable disease < 30% decrease or <20%
increase
- - Neither complete, nor partial nor progressive
lesion
Progressive disease ≥ 20% increase Lobulated thick
enhancement
- ≥ 20% increase OR Lobulated thick
enhancement
Table 2 Demographic and disease characteristics
Demographic and disease characteristics
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Demographics and disease characteristics are presented
with frequencies and percentages for categorical variables.
Continuous variables are presented with medians and
ranges.
Response rates are presented with a 95% confidence
interval calculated from the binomial distribution. The two
classification systems (change in lesion size and combined
criteria) were compared using the Stuart-Maxwell test at
each of the 163 follow-up evalaution as well as for the 28
patients.
All time-to-event analyses were calculated from the
start of treatment. Overall survival times were calculated
until death or the cut-off date (November 30, 2010), which-
ever came first. Time to progression for each patient was
calculated until the criteria for progression were met for
both the RECIST and combined criteria. Non-progressive
patients and those deceased from unrelated causes were
censored at last follow-up or at date of death. Progression-
free survival was calculated until the criteria for progression
were first met or until death. Patients who did not progress
or did not die were censored at last follow-up. Survival
rates were estimated with the Kaplan-Meier method.
Results
Twenty-eight patients presented with 40 lesions. Median
age was 63.5 years (range, 23–81 years) and 64% were
men (Table 2). The primary was colorectal cancer in 19
patients (68%), breast cancer in one patient (3.5%), and
other sites for eight patients (28.5%): pneumoblastoma,
melanoma, leiomyosarcoma, bronchial carcinoma, pul-
monary epidermoid carcinoma, epidermoid carcinoma
of the cavum, and endocrine carcinoma of the pancreas.
The number of lesions by patient were as follows: 19
patients (68%) had one lesion, seven patients (25%) had
two lesions, one patient (3.5%) had three lesions, and
one patient (3.5%) had four lesions. The median number
of evaluations was 6 (range 3 – 28).
Imaging findings
Contrast enhancement
At first follow-up, the shape of the lesion was almost
always the same: a hypodense center surrounded by aperipheral rim enhancement localized in a large hypo-
dense area with a clearly defined border between the
irradiated parenchyma and the normal liver, as schema-
tized in Figure 1a. This large hypodense area was seen
in 31/40 lesions. This depended mostly on the interval
between the treatment and the first CT; it was no longer
observable after 2 months. In one case of hepatic steato-
sis, this area was observed displaying hyperdensity. On
further follow-up, it became increasingly isodense with
the normal hepatic parenchyma, and then became
hyperdense again while continuously shrinking. This en-
hancement pattern was present in all patients treated
with CyberKnife regardless of prognosis.
After treatment, every lesion displayed a thin rim
enhancement at least in one of successive follow-up
images (Figures 2 and 3). On long-term observation, this
appearance remained stable in 30 lesions or, otherwise,
assumed a lobulated and thick manifestation resembling
a daisy in 10 lesions (Figure 4). Lobulated thick enhance-
ment was first seen at 3.7 months (median 7.6 months,
mean 9 months) after treatment. This enhancement
increased with time in every lesion that had it.
Figure 1 Schematic representation of the target-shaped lesion at 3 months (a), note the hypodense area and the surrounding rim
enhancement; after 3 months in case of local control(b,c), the lesion becomes smaller(b), retains its size, or even grows surrounded by
a thin rim enhancement with total necrosis (c); and (d) in case of local recurrence, note the heterogeneous center surrounded by
lobulated irregular thick enhancement; Note the shrinkage of the hypodense area that becomes hyperdense in all cases.
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Change in tumor size at each of the 163 follow-up eva-
luations along with the necrosis and contrast enhance-
ment information are presented in Table 3. Size-based
criteria identified 11 CR, 71 PR, 52 SD, and 29 PD.
According to the combined criteria, there were 23 cCR,
67 cPR, 45 cSD, and 28 cPD. Among the 71 lesions
categorized as PR (decrease of more than 30% in size),
four lesions were necrotic, 45 were cSD, and 11 were
cCR as judged by the combined criteria. All cPR and
cSD lesions showed a target-shaped morphology and
were distinctly surrounded by a well pronounced rim
enhancement, indicating local control, as shown in
Figures 1b and 2.
A total of eight (5%) lesions were classified as pseudo-
progressive, either because they stabilized after a period
of growth or were completely necrotic despite their
growth in size (Figures 1c and 3). These lesions were
among those classified as progressive (three lesions) or
stable (five lesions) according to the size-based criteria.
In two cases, blood vessels were observed to penetrate
these lesions without deformation, attesting to their
necrotic nature.
According to the combined criteria, there were 28
(17%) progressive lesions, 26 of which were diagnosed
based on a persistent size increase observed over
successive imaging and two lesions, although stable in
size, showed a lobulated thick heterogeneous enhance-
ment. All of the progressive lesions eventually exhib-
ited a lobulated thick heterogeneous enhancement,indicating strong likelihood for failure (Figures 1d
and 4).
Treatment response by patient
The complete response rate was 3.6% (95% CI: 0.1–18%)
according to RECIST criteria and 18% (95% CI: 6–37%)
according to the combined criteria. The distribution of
CR between the two sets of criteria were significantly
different (McNemar test, p = 0.046): two PDs and two
PRs according to RECIST were identified as CR accord-
ing to the combined criteria (Table 4; Figure 5). The
objective response rate was 50% (95% CI: 31–69%)
according to RECIST criteria and 57% (95% CI: 37–76%)
according to the combined criteria. The disease control
rate was 60.7% (95% CI: 41–78%) according to RECIST
and 64% (95% CI: 44–81%) according to the combined
criteria. The classification of progressive disease by the
two categories was not significantly different.
Overall survival
Median follow-up was 23.1 months (range 13 – 33).
Eight patients died (28.6%), six from disease progression
and two from other causes (one respiratory failure, one
hepatic failure leading to encephalopathy). Median over-
all survival was not reached. The 1- and 2-year survival
rates were 96.4% and 67.8%, respectively (Table 5).
Progression-free survival
Median progression-free survival for the 28 patients was
19.3 months according to RECIST and 19.1 months
Figure 2 Complete response after SBRT for a liver metastasis over successive follow-ups. Before treatment (a); 2 months later (b), we
observe changes of the initial phase: target-shaped lesion surrounded by a peripheral enhancement and located in a hypodense area with well
delineated demarcation between irradiated and normal liver; CT slices performed at portal phase at 5 months (c); 9 months (d); 12 months (e);
and 24 months later (f) show that the center is better circumscribed by a thin rim enhancement, the hypodense area progressively shrank and
became hyperdense.
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2-year progression-free survival rates were 67.9% and
47.2% using RECIST, and 71.4% and 43.2% using com-
bined criteria, respectively.
Time to progression
Thirteen patients had progressive disease or died from
disease progression according to both classifications.
Median time to progression was not reached according
to RECIST and was 19.3 month according to combined
criteria. The 1- and 2-year time-to-progression rates
were, respectively, 67.9% and 50.8% using RECIST, and
71.4% and 49.4% using combined criteria.
Discussion
Assessment of response to an oncologic treatment is usu-
ally based on international guidelines such as the World
Health Organization (WHO) guidelines or the Response
Evaluation Criteria in Solid Tumors (RECIST) group[10,12]. These criteria are based on the assessment of the
change in tumor size after treatment. However, they ap-
pear to be less adapted in assessing the efficacy of targeted
therapy, such as those for gastrointestinal stromal tumors
treated with anti-angiogenic agents [13].
Functional imaging such as FDG Positron Emission
Tomography (PET), contrast enhancement ultrasound
(CE US), and diffusion-weighted Magnetic Resonance
Imaging (MRI) are sensitive methods which allow an
early assessment of metabolic response for different
treatments [14-17]. However, these methods are avail-
able at only a limited number of institutions.
Along with other applications, SBRT is an excellent
noninvasive option for the treatment of inoperable
hepatic tumors [4,7].
Imaging studies play an integral role in monitoring re-
sponse to SBRT [18,19]. Traditionally, a decrease in tumor
size according to the RECIST criteria has been considered
CT evidence of treatment response 9, 10]. These criteria
Figure 3 Pseudo- progressive lesion after SBRT, before treatment (a), 2 months later (b), 6 months later (c, d), and 9 months later (e).
CT slices show the progressive size increase with a completely necrotic lesion.
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they are often inadequate in interpreting the results fol-
lowing local or targeted therapy [13,20-24].
Acknowledging the limitations of the size criteria,
some experts proposed considering lesion enhancement
in the evaluation of therapeutic response of malignant
tumors, such as modified RECIST (mRECIST) for he-
patocellular carcinoma (HCC) [24], the CHOI criteria
for gastrointestinal stromal tumors (GIST) [13], or the
CHUN criteria for colorectal metastases treated with
bevacizumab [25].
In this study, we observed the profile evolution of 40
liver lesions following SBRT. This way, we were able to
objectively distinguish the responsive lesions from the
progressive ones. The responsive lesions includedthose with complete necrosis, complete disappearance,
partial response, or stabilization; and also the pseudo-
progressive lesions that initially increased their size or
remained stable and yet were completely necrotic.
Our method for response evaluation combines size,
enhancement, and necrosis criteria based on the retro-
spective observation of SBRT-treated hepatic lesions.
Lesions were classified into four categories: CR, PR, and
SD for local control, and PD for local recurrence. A re-
sponse was considered complete if a lesion disappeared,
or the remaining tissue appeared completely necrotic
regardless of its size. Also according to combined
criteria, the occurrence of a lobulated enhancement
pattern around the lesion was considered PD regardless
of any change in lesion size. A size increase according
Figure 4 Progressive lesion after SBRT; a liver metastasis with a calcified center before treatment (a), 2 months later (b) we observe
the changes of the initial phase as described, 4 months (c) and 6 months later (d) CT slices show the Daisy Sign: a lobulated thick
peripheral enhancement.
Table 4 Treatment response using RECIST or combined
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progressive disease. For the combined criteria, partial
response and stable disease are identical to their coun-
terparts in the RECIST criteria. Owing to measurements
unreliability of CT attenuation coefficient for small
lesions, we did not consider necrosis criteria for
lesions ≤15 mm [26].
During the course of the study, we observed that if
the RECIST criteria were to be applied without question,
this may result in misinterpretation of some of the
responses to the treatment. For instance, a progressive
lesion according to the combined criteria was deemed
stable according to RECIST. Some of the perfectly
responsive lesions increased in size and were classified
as progressive according to RECIST, but we were able toTable 3 Lesions response according to change in tumor




Change in tumor size
CR PR SD PD Total,
n (%)
Combined criteria
cCR 11 4 5 3 23 (14.1%)
cPR 0 67 0 0 67 (41.1%)
cSD 0 0 45 0 45 (27.6%)
cPD 0 0 2 26 28 (17.2%)
Total, n (%) 11 (67.5%) 71 (43.6%) 52 (31.9%) 29 (17.8%)attribute this increase to necrosis, cystic degeneration,
hemorrhage, or edema [27]. Therefore, size increase was
not enough in and of itself as a criterion to indicate pro-
gression. In our study, two patients had lesions which
became completely necrotic but increased in size and
would have been erroneously categorized as PD based
on the traditional size criteria. These lesions did not
show any enhancement unlike the really progressive
lesions that increased in size yet stayed solid. Therefore,
it is sometimes necessary to use more diverse criteria
based on the morphological characteristics of a lesion






CR PR SD PD Total, n (%)
Combined criteria
cCR 1 2 0 2 5 (17.9%)
cPR 0 11 0 0 11 (39.3%)
cSD 0 0 2 0 2 (7.1%)
cPD 0 0 1 9 10 (35.7%)
Total, n (%) 1 (3.6%) 13 (46.4%) 3 (10.7%) 11 (39.3%)















CR PR SD PD
according to RECIST criteria or Combined criteria
Treatment response by patient
RECIST Combined criteria
Figure 5 Treatment response by patient according to RECIST and Combined criteria.
Table 5 Survival endpoints using RECIST or combined
criteria




Median [CI 95%] -
OS rate, % [CI 95%]
12 months 96 [77.2-99.5]
18 months 72. [51–86]
24 months 67 [44–82]
Progression-Free Survival
Progression or Death (every
cause)
14 15
Median [CI 95%] 19.3 [8.0-. . .] 19.1 [12.3-. . .]
PFS rate, % [CI 95%]
12 months 68 [47–82] 71 [51–85]
18 months 56 [36–72] 52 [32–69]
24 months 47 [27–65] 43 [24–61]
Time to Progression
Progression or death from disease
progression
13 13
Median [CI 95%] - 19.3 [12.3-. . .]
TTP rate, % [CI 95%]
12 months 68 [47–82] 71 [51–85]
18 months 60 [40–76] 60 [39–75]
24 months 51 [30–68] 49 [28–67]
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results section is a morphologic sign based on the lesion
enhancement shape that is easy to identify by contour-
ing the outline of a lesion. This pattern seemed to be a
sensitive and specific sign for assessment of local
relapse, which well correlated with size changes in 9/10
patients. Lobulated enhancement could sometimes
allow earlier identification of local recurrence. In 2/10
patients, the lobulated enhancement appeared earlier
than size progression, at the same time for 7/10
patients, and later in 1/10 patient. In this last case, the
telltale sign was difficult to spot because of the lesion’s
location that contained no surrounding parenchyma.
The determination of the sensitivity and specificity of
this pattern needs further studies with a larger number
of progressive lesions. This pattern may have been
detected earlier than the enlargement in size if an inter-
mediate CT scan between 6th and 9th months had been
recorded. In fact, on analysis of the progression-free
survival curves, the drop in the curve with the two
methods of evaluation occurring between the 6th and
9th months suggests that this period may be important
in the surveillance of the lesions, and the insertion of an
extra CT scan during this period may be instrumental
in earlier detection of a possible failure. This way, an
earlier medical intervention could also be initiated.
Total necrosis was also easy to spot by measuring
with an objective method the density of the lesion
before and after contrast injection: a difference ≤10 H
indicated no enhancement, therefore, necrotic charac-
teristics. This method could not be used for small
lesions that were <15 mm, in which case the measure-
ments became unreliable. The necrosis criterion












28 19 8 3 0RECIST
28 20 7 2 0Combined criteria
Number at risk




Figure 6 Progression-free survival according to combined criteria and RECIST criteria.
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on their size increase.
The thin rim enhancement was seen in all lesions in
our study. This finding is likely due to the presence of
granulation tissue related to inflammatory response to
the treatment [28].Our findings are consistent with the
literature. For instance, Olsen et al. [28] have described
a zonal pattern of SBRT injury in two patients treated
by SBRT and who underwent surgery. Herfarth et al.
[29] have described three different types of reaction
based on the time of imaging after SBRT corresponding
to the histological changes seen in veno-occlusive
disease (VOD). The results of our study matches those
of Herfarth fairly well. The VOD that was initially seen
as a hypodense area would become fibrotic, becoming
smaller and denser as seen on successive follow-ups. InFigure 7 Algorithm using combined criteria for assessing local respononly one patient who had a case of fatty infiltration of
the liver, the CT showed a relatively increased density of
the surrounding area in the portal phase. This has also
been described by Yamasaki in 2/31 patients treated by
conformal radiation therapy [30]. A distinct border
between the target and normal parenchyma was always
visible at the treatment margin. This phenomenon
also attested to the CyberKnife beams’ accuracy of
distribution.
There was no statistical difference in classification of
progressive disease using RECIST criteria and combined
criteria due to the small number of progressive lesions
(n = 10 for the combined criteria and n = 11 for
RECIST). Nevertheless, the use of the combined criteria
led to a more accurate detection of response and
progression than the use of RECIST criteria. Amongse for liver metastasis treated by SBRT.
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(n = 11), necrosis and enhancement criteria allowed to
differentiate between progressive (n = 9 PD) and
pseudo-progressive lesions (n = 2 CR). A display of
complete necrosis proves a lesion is in complete response.
On the other hand, the lobulated thick enhancement can
be useful for confirmation of progression when progres-
sion is suspected based on the size criterion.
Although the response rates excluding SD according
to size criteria were relatively low (46%), in most of the
patients (60.7%), the lesion size stabilized after SBRT.
A stable lesion is considered beneficial for a patient
whose lesion was progressive before the treatment and
would have progressed if the treatment had not been
implemented. The response rates, including SD, were
not statistically different, 61% according to RECIST
criteria and 64% according to combined criteria.
In this study, the median survival duration was not
reached. The 1- and 2-year overall survival rates were 96%
and 67%, respectively. In order to achieve at least 2 years
of follow up, we included some patients treated at the be-
ginning of our SBRT practice at which time the patients
were treated at a lower dose than in our current practice.
However, if we were to report on the complete cohort
treated at our center [6], which included 99 lesions in 72
patients until April 2010, the median progression-free sur-
vival was 10.5 months, reached by patients who had failed
multiple regimens of chemotherapy. The overall survival
rate was 72% at 1 year and 65% at 2 years. These survival
results are consistent with those previously reported for
patients with unresectable liver metastases [5,7,8,18].
These encouraging results should be considered with the
selection criteria for the patients eligible for SBRT in
mind. These patients usually have good performance sta-
tus with long disease history, metastases only in the liver
or a limited number of other metastases.
A strategy for the assessment of local response of hep-
atic metastasis to SBRT is proposed in the algorithm
below (Figure 7). In ambiguous cases, follow-up studies
would either show the resolution of treatment-related
inflammatory changes or an area of persistent enhance-
ment or a residual continuously growing tumor.
This retrospective study has the usual limitations
associated with this type of studies. Histopathological
confirmation of imaging findings after therapy was not
attempted because of the potential for sampling error.
Furthermore, a biopsy was considered too invasive
without significant effect on future management. The
patient sample was limited to the patients who had at
least 2 years of follow-up and lesions larger than 1 cm.
Response was assessed on the data from successive
follow-ups conducted during at least 2 years. SD based
on imaging at 2 years was considered local control
without histopathological confirmation.The response assessment criteria were developed
based on retrospective observation performed by one
radiologist. Because the described lobular enhancement
pattern is subject to interpretation, it is necessary to
further confirm their validity prospectively in a larger
population of patients and with many radiologists.
Conclusions
SBRT is an emerging technique for treatment of unre-
sectable liver malignancies, especially liver metastases.
The interpretation of post therapeutic imaging features
may be challenging for radiologists. The size-based
RECIST criteria are not always appropriate in inter-
preting imaging follow-up of local treatments such as
SBRT. Instead we developed a new set of criteria based
on a characteristic enhancement pattern on contrast
CT combined with the size-based RECIST. These new
combined criteria, which need further studies to be
validated, may prevent some of the errors that may
result from misinterpretation with size-based criteria
alone.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HJ, XM, ST, LC conceived the study. HJ collected data. HJ drafted the
manuscript. XM, AA, SD, FB, ST, AK, LC and EL participated in coordination
and helped to draft the manuscript. AK and ET performed the statistical
analyses. EL, AA and LC provided mentorship and edited the manuscript. All
authors have read and approved the final manuscript.
Acknowledgements
Acknowledgement to Mikail H. Gezginci, MPharm, PhD.
Author details
1Department of Radiology, CLCC Oscar Lambret, 3 rue Frédéric Combemale,
BP 307, Lille cedex 59020, France. 2Department of Radiotherapy, CLCC Oscar
Lambret, 3 rue Frédéric Combemale, BP 307, Lille cedex 59020, France.
3Department of Methodology and Biostatistics, CLCC Oscar Lambret, 3 rue
Frédéric Combemale, BP 307, Lille cedex 59020, France. 4Department of
digestive oncology, CLCC Oscar Lambret, 3 rue Frédéric Combemale, BP 307,
Lille cedex 59020, France.
Received: 19 December 2012 Accepted: 22 January 2013
Published: 30 January 2013
References
1. Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M:
Management of cerebral metastasis: evidence-based approach for
surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011,
47:649–655.
2. Feuvret L, Noel G, Nauraye C, Garcia P, J-Mazeron J: [Conformal index and
radiotherapy]. Cancer Radiother 2004, 8:108–119.
3. Ruers T, Bleichrodt RP: Treatment of liver metastases, an update on the
possibilities and results. Eur J Cancer 2002, 38:1023–1033.
4. Sawrie SM, Fiveash JB, Caudell JJ: Stereotactic body radiation therapy for
liver metastases and primary hepatocellular carcinoma: normal tissue
tolerances and toxicity. Cancer Control 2010, 17:111–119.
5. Fuss M, Thomas CR Jr: Stereotactic body radiation therapy: an ablative
treatment option for primary and secondary liver tumors. Ann Surg Oncol
2004, 11:130–138.
6. Vautravers-Dewas C, Dewas S, Bonodeau F, Adenis A, Lacornerie T, Penel N,
Lartigau E, Mirabel X: Image-guided robotic stereotactic body radiation
Jarraya et al. Radiation Oncology 2013, 8:24 Page 11 of 11
http://www.ro-journal.com/content/8/1/24therapy for liver metastases: is there a dose response relationship?
Int J Radiat Oncol Biol Phys 2011, 81:e39–47.
7. Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P,
Casamassima F, Febbraro A, Gerunda G, Lumachi F: Image-guided robotic
stereotactic radiosurgery for unresectable liver metastases: preliminary
results. Anticancer Res 2009, 29:3381–3384.
8. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC,
Fisher GA, Koong AC: Dose-escalation study of single-fraction stereotactic
body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010,
78:486–493.
9. Goyal K, Einstein D, Yao M, Kunos C, Barton F, Singh D, Siegel C, Stulberg J,
Sanabria J: Cyberknife stereotactic body radiation therapy for
nonresectable tumors of the liver: preliminary results. HPB Surg 2010,
2010:pii 309780.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer
treatment. Cancer 1981, 47:207–214.
11. Chung EP, Herts BR, Linnell G, Novick AC, Obuchowski N, Coll DM, Baker ME:
Analysis of changes in attenuation of proven renal cysts on different
scanning phases of triphasic MDCT. AJR Am J Roentgenol 2004,
182:405–410.
12. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD: Revised
RECIST guideline version 1.1: What oncologists want to know and what
radiologists need to know. AJR Am J Roentgenol 2010, 195:281–289.
13. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson
MM, Macapinlac HA, Podoloff DA: CT evaluation of the response of
gastrointestinal stromal tumors after imatinib mesylate treatment: a
quantitative analysis correlated with FDG PET findings. AJR Am J
Roentgenol 2004, 183:1619–1628.
14. Coenegrachts K: Magnetic resonance imaging of the liver: New imaging
strategies for evaluating focal liver lesions. World J Radiol 2009, 1:72–85.
15. Caretti V, Zondervan I, Meijer DH, Idema S, Vos W, Hamans B, Bugiani M,
Hulleman E, Wesseling P, Vandertop WP, Noske DP, Kaspers G, Molthoff CF,
Wurdinger T: Monitoring of tumor growth and post-irradiation
recurrence in a diffuse intrinsic pontine glioma mouse model. Brain
Pathol 2011, 21:441–451.
16. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ,
Smit EF, Hoekstra OS, Lammertsma AA, Boellaard R: Measuring response to
therapy using FDG PET: semi-quantitative and full kinetic analysis.
Eur J Nucl Med Mol Imaging 2011, 38:832–842.
17. Padhani AR, Koh DM: Diffusion MR imaging for monitoring of treatment
response. Magn Reson Imaging Clin N Am 2011, 19:181–209.
18. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg
SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE: Multi-
institutional phase I/II trial of stereotactic body radiation therapy for liver
metastases. J Clin Oncol 2009, 27:1572–1578.
19. Lee MT, Kim JJ, Dinniwell R, Ley J, Lockwood G, Wong R, Cummings B,
Ringash J, Tse RV, Knox JJ, Dawson LA: Phase I study of individualized
stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009,
27:1585–1591.
20. Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, Sato M,
Yamanaka N, Shimamura Y, Ohto M: Comparison of CT findings with
resected specimens after chemoembolization with iodized oil for
hepatocellular carcinoma. AJR Am J Roentgenol 2000, 175:699–704.
21. Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, Petrow P,
Roche A, Sigal R: Hepatic tumors treated with percutaneous radio-
frequency ablation: CT and MR imaging follow-up. Radiology 2002,
223:255–262.
22. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, Zajko A:
Evaluation of responses to chemoembolization in patients with
unresectable hepatocellular carcinoma. Cancer 2003, 97:1042–1050.
23. Kalb B, Chamsuddin A, Nazzal L, Sharma P, Martin DR: Chemoembolization
follow-up of hepatocellular carcinoma with MR imaging: usefulness of
evaluating enhancement features on one-month posttherapy MR
imaging for predicting residual disease. J Vasc Interv Radiol 2010,
21:1396–1404.
24. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for
hepatocellular carcinoma. Semin Liver Dis 2010, 30:52–60.
25. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M,
Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM: Association of
computed tomography morphologic criteria with pathologic responseand survival in patients treated with bevacizumab for colorectal liver
metastases. JAMA 2009, 302:2338–2344.
26. Siegel CL, Fisher AJ, Bennett HF: Interobserver variability in determining
enhancement of renal masses on helical CT. AJR Am J Roentgenol 1999,
172:1207–1212.
27. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ: Evaluating 90Y-glass
microsphere treatment response of unresectable colorectal liver
metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl
Med Mol Imaging 2002, 29:815–820.
28. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR,
Gaspar LE, Schefter TE: Microscopic and macroscopic tumor and
parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat
Oncol Biol Phys 2009, 73:1414–1424.
29. Herfarth KK, Hof H, Bahner ML, Lohr F, Höss A, van Kaick G, Wannenmacher
M, Debus J: Assessment of focal liver reaction by multiphasic CT after
stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol
Biol Phys 2003, 57:444–451.
30. Yamasaki SA, Marn CS, Francis IR, Robertson JM, Lawrence TS: High-dose
localized radiation therapy for treatment of hepatic malignant tumors:
CT findings and their relation to radiation hepatitis. AJR Am J Roentgenol
1995, 165:79–84.
doi:10.1186/1748-717X-8-24
Cite this article as: Jarraya et al.: Image-based response assessment of
liver metastases following stereotactic body radiotherapy with
respiratory tracking. Radiation Oncology 2013 8:24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
